Reducing polypharmacy through the introduction of a treatment algorithm: Use of a treatment algorithm on the impact on polypharmacy

Annals of the Academy of Medicine Singapore

Volumn 35, Issue 7, 2006, Pages 457-460

  Chong, Siow Ann ^a   Ravichandran, Nigila ^a   Poon, Lye Yin ^a   Soo, Kai Ling ^b   Verma, Swadna ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antipsychotics; Drug use review; Psychosis

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ADULT; ALGORITHM; ARTICLE; ASIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; POLYPHARMACY; PRESCRIPTION; PSYCHOSIS;

EID: 33749008778     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64:984-9.
2. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-9.
3. Chong SA, Sachdev P, Mahendran R, Chua HC. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust N Z J Psychiatry 2000;34:988-91.
4. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;261:700-6.
5. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenic patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88.
6. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004;58:178-83. Erratum in: Br J Clin Pharmacol 2004;58:564.
7. Binder RL, Kazamatusuri H, Nishmura T, McNeil DE. Tardive dyskinesia and neuroleptic-induced Parkinsonism in Japan. Am J Psychiatry 1987;144:1494-6.
8. Sim K, Su A, Ungvari GS, Fujii S, Yang S, Chong MY, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol Clin Exp 2004;19:103-9.
9. Fruedenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30.
10. Sernyak M, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004;65:1597-600.
11. Sernyak MJ, Dausey D, Desai R, Rosenheck R. Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv 2003;54:246-8.
12. Ito H, Koyama AA, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005;187:243-7.
13. International Early Psychosis Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry 2005;(Suppl 48):120-4.
14. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the treatment of schizophrenia and related disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1-30.
15. Clinical Practice Guidelines for Schizophrenia. Ministry of Health (Singapore) Clinical Practice Guidelines 2/2003;29.
16. Spencer E, Birchwood M, McGovern D. Management of first-episode psychosis. Adv Psych Treatment 2001;7:133-40.
17. McGorry P, Nordentoft M, Simonsen E. Introduction to 'Early psychosis: abridge to the future'. Br J Psychiatry 2005;187(Suppl 48):1-3.
18. Chiles JA, Miller AL, Crismon ML, Rush AJ, Krasnoff AS, Shon SS. The Texas medication algorithm project: development and implementation of the schizophrenia algorithm. Psychiatr Serv 1999;5:69-74.
19. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-8.
20. Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M, Crismon ML, et al. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry 2001;62:439-47.
21. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10.
22. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21:567-77.
23. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
24. Simpson GN, Angus JW. A rating scale for extra pyramidal side effects. Acta Psychiatr Scand 1970;212(Suppl):11-9.
25. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 2003;37:951-5.
26. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication in schizophrenia. Br J Psychiatry 2005;187:137-42.
27. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877-93.
28. Fifer S, Marken P, Kamanitz J, Kotin A, Thomas N. Rising mental health drug costs: how should managed care respond? Drug Benefit Trends 2005;17:311-6.
29. Prien RF, Baiter MB, Caffey EM. Hospital surveys of prescribing practices with psychotherapeutic drugs. Arch Gen Psychiatry 1978;35:1271-5.
30. Loosbrock DL, Zhao Z, Johnstone BM, Morris LS. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia J Ment Health Policy Econ 2003;6:67-75.